Gossamer Bio, Inc. (GOSS) stock
GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.97−0.27 (-2.40%)
Close on Nov 13, 2026Market cap $67.10MP/E –Yield –
Gossamer Bio ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Gossamer Bio's ebitda for the twelve months ending Mar 31, 2026 was -$178.76M. For fiscal 2025 it was -$170.70M. The highest annual figure on record is -$59.09M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$170.70M | – |
| FY2024 | Dec 31, 2024 | -$59.09M | – |
| FY2023 | Dec 31, 2023 | -$182.15M | – |
| FY2022 | Dec 31, 2022 | -$216.76M | – |
| FY2021 | Dec 31, 2021 | -$214.38M | – |
| FY2020 | Dec 31, 2020 | -$232.55M | – |
| FY2019 | Dec 31, 2019 | -$185.22M | – |
| FY2018 | Dec 31, 2018 | -$148.70M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$44.86M | – |
| Q4 FY2025 | Dec 31, 2025 | -$46.03M | – |
| Q3 FY2025 | Sep 30, 2025 | -$49.11M | – |
| Q2 FY2025 | Jun 30, 2025 | -$38.76M | -174.0% |
| Q1 FY2025 | Mar 31, 2025 | -$36.80M | – |
| Q4 FY2024 | Dec 31, 2024 | -$36.02M | – |
| Q3 FY2024 | Sep 30, 2024 | -$33.72M | – |
| Q2 FY2024 | Jun 30, 2024 | $52.39M | – |
| Q1 FY2024 | Mar 31, 2024 | -$41.70M | – |
| Q4 FY2023 | Dec 31, 2023 | -$48.74M | – |
| Q3 FY2023 | Sep 30, 2023 | -$40.09M | – |
| Q2 FY2023 | Jun 30, 2023 | -$45.80M | – |
| Q1 FY2023 | Mar 31, 2023 | -$47.48M | – |
| Q4 FY2022 | Dec 31, 2022 | -$53.90M | – |
| Q3 FY2022 | Sep 30, 2022 | -$55.52M | – |
| Q2 FY2022 | Jun 30, 2022 | -$53.37M | – |
| Q1 FY2022 | Mar 31, 2022 | -$53.89M | – |
| Q4 FY2021 | Dec 31, 2021 | -$51.21M | – |
| Q3 FY2021 | Sep 30, 2021 | -$55.16M | – |
| Q2 FY2021 | Jun 30, 2021 | -$55.20M | – |
| Q1 FY2021 | Mar 31, 2021 | -$52.79M | – |
| Q4 FY2020 | Dec 31, 2020 | -$59.72M | – |
| Q3 FY2020 | Sep 30, 2020 | -$53.20M | – |
| Q2 FY2020 | Jun 30, 2020 | -$64.99M | – |
| Q1 FY2020 | Mar 31, 2020 | -$54.64M | – |
| Q4 FY2019 | Dec 31, 2019 | -$55.50M | – |
| Q3 FY2019 | Sep 30, 2019 | -$49.74M | – |
| Q2 FY2019 | Jun 30, 2019 | -$46.14M | – |
| Q1 FY2019 | Mar 31, 2019 | -$33.85M | – |
| Q4 FY2018 | Dec 31, 2018 | -$39.67M | – |
| Q3 FY2018 | Sep 30, 2018 | -$49.90M | – |
| Q2 FY2018 | Jun 30, 2018 | -$33.00M | – |
| Q1 FY2018 | Mar 31, 2018 | -$26.12M | – |
See a number that looks wrong?